Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Agamree Emflaza Coverage | Open…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Agamree and Emflaza Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization, renewal, and quantity-limit criteria for Agamree and Emflaza under the Boeing commercial formulary.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAgamree and Emflaza Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit genetic confirmation of Duchenne muscular dystrophy and document six months of inadequate response to generic prednisone or prednisolone, unless an allowed exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moApproval length
    300 mLAgamree limit
    30 tabsEmflaza 18 mg limit
    60 tabsEmflaza 6 mg limit
    DMD

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered diagnosis

    Coverage Criteria

    Initial therapy

    Initial evaluation: target agents will be approved when ALL of the following are met.

    Initial clinical eligibility

    • Qualifying diagnosis or indication

      • The patient has Duchenne muscular dystrophy confirmed by genetic analysis showing a dystrophin deletion or duplication mutation.Genetic test required
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
    • Age requirement for an FDA-labeled indication

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for use of the requested agent for the patient's age and the requested indication.
    • Prerequisite-agent requirement

      • The patient tried and had an inadequate response to one prerequisite agent, generic prednisone or prednisolone, after 6 months of therapy.6 months
      • The patient has an intolerance or hypersensitivity to one prerequisite agent.
      • The patient has an FDA-labeled contraindication to all prerequisite agents.
    • Brand-over-generic requirement

      • The patient has an intolerance or hypersensitivity to the generic equivalent that is not expected to occur with the requested brand agent.
      • The patient has an FDA-labeled contraindication to the generic equivalent that is not expected to occur with the requested brand agent.
      • There is support for use of the requested brand agent over the generic equivalent.
    • Provider, safety, and dose requirements

      • The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, OR the prescriber has consulted with a specialist in the area of the patient's diagnosis.
      • The patient does not have any FDA-labeled contraindication to the requested agent.
      • The requested dose does not exceed the maximum FDA-labeled dose based on the patient's weight.

    Continuation therapy

    Renewal evaluation: target agents will be approved when ALL of the following are met.

    Renewal eligibility

    • Prior approval and clinical benefit

      • The patient was previously approved for the requested agent through the plan's prior authorization process.

        Patients not previously approved for the requested agent require initial evaluation review.

      • The patient has had clinical benefit with the requested agent.
    • Brand-over-generic requirement

      • The patient has an intolerance or hypersensitivity to generic deflazacort that is not expected to occur with Emflaza.
      • The patient has an FDA-labeled contraindication to generic deflazacort that is not expected to occur with Emflaza.

    Quantity-limit approval

    Quantity-limit approval: ONE of the following must be met.

    Quantity-limit approval pathways

    • Standard quantity-limit pathways

      • The requested quantity does not exceed the program quantity limit.
      • The requested agent strength does not have a program quantity limit.
    • Emflaza-specific exception

      • The requested agent is Emflaza suspension.
      • Tablet-strength exception

        • The requested quantity exceeds the program quantity limit.

    Dose and Prerequisite Parameters

    Prerequisite Therapy
    Duration6 months
    Prerequisite agentsGeneric prednisone or prednisolone
    Required outcomeInadequate response after therapy
    Maximum FDA-Labeled Dose
    Dose requirementMust not exceed the maximum FDA-labeled dose
    Dose basisPatient's weight
    Quantity-limit relationshipThe requested dose must also satisfy applicable quantity-limit criteria

    Provider Requirements and Denial Risks

    Documentation Required

    Document a Qualifying Diagnosis or Indication

    Document that the requested agent is medically appropriate for a qualifying diagnosis or FDA-labeled indication. Duchenne muscular dystrophy must be confirmed by genetic analysis showing a dystrophin deletion or duplication mutation.

    • Provide genetic-test documentation for genetically confirmed Duchenne muscular dystrophy.
    • For another FDA-labeled indication, document the indication and requested route of administration.
    • If the patient's age is outside FDA labeling, provide support for use at the patient's age and for the requested indication.
    Step Therapy

    Meet the Prerequisite Corticosteroid Requirement

    Document that the patient has met the prerequisite corticosteroid requirement before requesting the target agent. An exception may apply for intolerance, hypersensitivity, or an FDA-labeled contraindication to the prerequisite therapy.

    • Document an inadequate response after 6 months of therapy with one prerequisite agent; or

    Policy Background

    This policy applies to Agamree (vamorolone oral suspension) and Emflaza (deflazacort suspension or tablets) under the Boeing commercial formulary. Coverage is available through prior authorization for Duchenne muscular dystrophy confirmed by genetic analysis showing a dystrophin deletion or duplication mutation, or for another FDA-labeled indication and route when the patient’s age is within labeling or otherwise supported for the requested use. Approval also requires applicable prerequisite-agent history or an allowed exception, specialist involvement, absence of FDA-labeled contraindications, dosing within the maximum FDA-labeled dose based on weight, and compliance with applicable quantity limits.

    Key Definitions

    Genetically Confirmed Duchenne Muscular Dystrophy
    ConditionDuchenne muscular dystrophy
    Required confirmationGenetic analysis confirming a dystrophin deletion or duplication mutation
    Testing requirementGenetic test required
    Program Quantity Limit
    DefinitionThe maximum quantity allowed by the program
    Applies toA specified strength
    Supply period30-day supply

    Initial Therapy Criteria

    Initial evaluation

    Initial approval requires ALL applicable clinical criteria.

    Initial Agamree or Emflaza approval

    • Qualifying diagnosis or indication

      • The patient has Duchenne muscular dystrophy confirmed by genetic analysis showing a dystrophin deletion or duplication mutation.Genetic test required
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
    • Age requirement for an FDA-labeled indication

      • The patient's age is within FDA labeling for the requested indication for the requested agent.

    Continuation Criteria

    Renewal evaluation

    Renewal is approved when ALL of the following are met.

    Continuation therapy

    • Prior approval and clinical benefit

      • The patient was previously approved for the requested agent through the plan's prior authorization process.

        Patients not previously approved for the requested agent require initial evaluation review.

      • The patient has had clinical benefit with the requested agent.
    • Brand-over-generic requirement

      • The patient has an intolerance or hypersensitivity to generic deflazacort that is not expected to occur with Emflaza.

    Step-Therapy Requirement

    StepPrerequisite therapyRequirement and exceptions
    1Generic prednisone or prednisoloneTry for 6 months and document an inadequate response. This step may be bypassed if the patient has intolerance or hypersensitivity to a prerequisite agent, or an FDA-labeled contraindication to all prerequisite agents.

    Quantity Limits

    Agamree Quantity Limit
    AgentAgamree (vamorolone oral suspension) 40 mg/mL
    Quantity limit300 mL
    Day supply30 days
    Emflaza 18 mg Quantity Limit
    AgentEmflaza (deflazacort tablets) 18 mg
    Quantity limit30 tablets
    Day supply30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyAgamree and Emflaza Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit genetic confirmation of Duchenne muscular dystrophy and document six months of inadequate response to generic prednisone or prednisolone, unless an allowed exception applies.
    SourceLink
    On This Page
    Coverage CriteriaDose and Prerequisite ParametersProvider Requirements and Denial RisksPolicy BackgroundKey DefinitionsInitial Therapy CriteriaContinuation CriteriaStep-Therapy RequirementQuantity Limits
  1. There is support for use of Emflaza over generic deflazacort.
  2. Provider, safety, and dose requirements

    • The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, OR the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindication to the requested agent.
    • The requested dose does not exceed the maximum FDA-labeled dose based on the patient's weight.
  3. The requested quantity cannot be achieved with a lower quantity of any combination of the four Emflaza tablet strengths.
  4. Higher-strength dose-construction exception

    • The requested quantity exceeds the program quantity limit.
    • The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication.
    • The requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  5. Document intolerance or hypersensitivity to one prerequisite agent; or
  6. Document an FDA-labeled contraindication to all prerequisite agents.
  7. Documentation Required

    Support the Brand Emflaza Exception

    For brand Emflaza, provide documentation supporting use over the available generic equivalent, deflazacort. The rationale must be specific to the patient and not merely a preference for the brand product.

    • Document intolerance or hypersensitivity to generic deflazacort that is not expected with Emflaza; or
    • Document an FDA-labeled contraindication to generic deflazacort that is not expected with Emflaza; or
    • Provide clinical support for using Emflaza over generic deflazacort.
    Prior Authorization

    Confirm Specialist Oversight and Safety

    Ensure the prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, or document consultation with an appropriate specialist. Also confirm that the patient has no FDA-labeled contraindication to the requested agent and that the requested dose is within FDA-labeled limits based on weight.

    • Specialist prescribing or specialist consultation is required.
    • Review the requested agent for FDA-labeled contraindications.
    • Verify dose compliance with the maximum FDA-labeled dose for the patient's weight.
    Step Therapy

    Document Prednisone or Prednisolone Prerequisite

    Document use of one prerequisite agent—generic prednisone or prednisolone—before the requested target agent, unless an allowed exception applies. The record must show the outcome or reason the prerequisite could not be used.

    • Inadequate response after 6 months of generic prednisone or prednisolone qualifies as a step-therapy history.
    • Intolerance or hypersensitivity to prednisone or prednisolone may qualify for an exception.
    • An FDA-labeled contraindication to all prerequisite agents may qualify for an exception.
    Documentation Required

    Provide Diagnosis and Indication Documentation

    Submit documentation establishing the patient's diagnosis and the requested agent's applicable indication. For Duchenne muscular dystrophy, the documentation must include genetic confirmation of a dystrophin deletion or duplication mutation.

    • Include the diagnosis, relevant clinical records, and requested route of administration.
    • For an FDA-labeled indication, document that the patient's age is within labeling or provide support for use at the patient's age.
    Documentation Required

    Document Prerequisite-Agent History

    Include a clear history of the prerequisite-agent trial or the qualifying reason a trial was not possible. The history should identify the agent, duration, response, and any intolerance, hypersensitivity, or contraindication.

    • Identify generic prednisone or prednisolone as the prerequisite agent when applicable.
    • Document an inadequate response after 6 months, or the specific exception supporting nontrial or discontinuation.
    • Do not rely on an undocumented or nonspecific statement that prerequisite therapy was tried.
    Documentation Required

    Document Specialist and Brand Requirements

    Document specialist involvement and, when requesting brand Emflaza, provide the required brand-over-generic rationale. The specialist requirement and brand exception apply during applicable initial and renewal reviews.

    • Identify the diagnosing specialist as prescriber or document consultation with a specialist, such as a pediatric neurologist.
    • For Emflaza, compare the requested brand with generic deflazacort and document a qualifying intolerance, contraindication, or clinical support for the brand.
    Documentation Required

    Document Dose, Weight, and Quantity

    Provide the patient's current weight, prescribed dose, strength, frequency, and requested quantity. The requested dose must not exceed the maximum FDA-labeled dose based on weight, and quantity-limit requests must include the applicable quantity rationale.

    • Document patient weight and the calculation supporting the requested dose.
    • For quantity-limit exceptions, show why the dose cannot be achieved with a lower quantity of available strengths when required.
    • For Emflaza, identify whether the request is for suspension or tablets and document the applicable strength and quantity.
    Denial Risk

    Failure to Meet Clinical Criteria May Result in Denial

    Requests that do not satisfy the clinical criteria may be denied. Initial requests require a qualifying diagnosis or indication, prerequisite-agent criteria, brand requirements when applicable, specialist involvement, safety review, and dose compliance; renewals also require prior plan approval and documented clinical benefit.

    • Document clinical benefit and prior approval for renewal requests.
    • Failure to meet any required clinical criterion may result in denial.
    • Patients not previously approved through the plan's prior authorization process require initial evaluation review.
    Denial Risk

    Quantity-Limit Noncompliance May Result in Denial

    Requests that do not meet the program quantity-limit criteria may be denied. Document that the requested quantity is within the limit or establish an applicable exception for the strength, Emflaza formulation, or dose-construction circumstances.

    • The quantity must not exceed the program limit unless an exception applies.
    • An exception may apply when the requested strength has no program quantity limit.
    • For Emflaza, document suspension use or why the requested dose cannot be achieved with a lower quantity of any combination of the four tablet strengths.
    • For other requests, document that the dose does not exceed the maximum FDA-labeled dose and cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    Denial Risk

    Insufficient Brand-Over-Generic Rationale May Result in Denial

    A request for brand Emflaza may be denied when the submission does not provide sufficient clinical rationale for using Emflaza instead of generic deflazacort. Brand preference alone is not sufficient.

    • Document a brand-specific intolerance or hypersensitivity that is not expected with generic deflazacort; or
    • Document a brand-specific FDA-labeled contraindication that is not expected with generic deflazacort; or
    • Provide clinical evidence or rationale supporting Emflaza over generic deflazacort.
    ExceptionsSubject to stated quantity-limit exceptions
  8. There is support for use of the requested agent for the patient's age and the requested indication.
  9. Prerequisite-agent requirement

    • The patient tried and had an inadequate response to one prerequisite agent, generic prednisone or prednisolone, after 6 months of therapy.6 months
    • The patient has an intolerance or hypersensitivity to one prerequisite agent.
    • The patient has an FDA-labeled contraindication to all prerequisite agents.
  10. Brand-over-generic requirement

    • The patient has an intolerance or hypersensitivity to the generic equivalent that is not expected to occur with the requested brand agent.
    • The patient has an FDA-labeled contraindication to the generic equivalent that is not expected to occur with the requested brand agent.
    • There is support for use of the requested brand agent over the generic equivalent.
  11. Provider, safety, and dose requirements

    • The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, OR the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindication to the requested agent.
    • The requested dose does not exceed the maximum FDA-labeled dose based on the patient's weight.
  12. The patient has an FDA-labeled contraindication to generic deflazacort that is not expected to occur with Emflaza.
  13. There is support for use of Emflaza over generic deflazacort.
  14. Provider, safety, and dose requirements

    • The prescriber is a specialist in the area of the patient's diagnosis, such as a pediatric neurologist, OR the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindication to the requested agent.
    • The requested dose does not exceed the maximum FDA-labeled dose based on the patient's weight.
  15. Emflaza 6 mg Quantity Limit
    AgentEmflaza (deflazacort tablets) 6 mg
    Quantity limit60 tablets
    Day supply30 days